Industry Update: Biotechnology
VRC is proud to release its latest industry report. The report provides a concise, insightful update on the Biotechnology industry including recent transactions, market multiples, company performance and purchase price allocation percentages.
I
ndustry Highlights
- On December 28, 2021, Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. for approximately $3.2 billion. Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain.
- On December 14, 2021, Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therapies, announced that they have entered into a definitive agreement for CSL to launch an all-cash public tender offer to acquire allVifor Pharma shares for US$179.25 per share, or approximately $11.7 billion.
